Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced positive results for the second Phase III study of tasimelteon for the treatment of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE